Eli Lilly PM system design interview how to approach and examples 2026

Eli Lilly PM System Design Interview: How to Approach and Examples 2026

What Makes Eli Lilly System Design Different From Tech Companies?

In a Q3 2024 debrief, a hiring manager rejected a candidate from Google who designed a beautiful real-time adverse event reporting system with sub-100ms latency. The candidate had sketched Kafka streams, auto-scaling groups, and elegant circuit breakers. The debrief stalled when the hiring manager asked: "Where is the electronic signature? Where is the audit trail? How does this system maintain data integrity if a node fails during an FDA inspection?" The candidate had never heard of ALCOA+ principles. The hire was a no.

Lilly's system design interviews embed three structural constraints that tech PMs consistently underestimate. First, every data point that could influence a regulatory decision must have attributable, legible, contemporaneous, original, and accurate documentation—the ALCOA+ standard. Second, software systems in regulated environments require validation (CSV, Computer System Validation), meaning you cannot iterate your way out of a design; you must prove it works before deployment. Third, patient safety events have statutory reporting timelines—serious adverse events to FDA within 15 calendar days, for example—which create hard real-time requirements that differ from consumer product SLAs.

The framework that separates successful candidates is what I call "Compliance-First Architecture." Not compliance as a checkbox at the end, but compliance as the load-bearing wall of your design. When you draw your system diagram, the first box should be the audit trail. The second should be identity and access management with electronic signatures. Only then do you layer functional requirements.

The second counter-intuitive truth: Lilly interviewers will deliberately introduce constraints that seem absurd in tech. "What if the FDA inspector is sitting in this room tomorrow?" "What if we need to reconstruct this decision three years from now?" These are not hypothetical edge cases. In 2023, Eli Lilly faced FDA inspection findings related to data integrity in manufacturing systems. The organization is still hypersensitive to documentation gaps. Your system design must demonstrate that you have internalized this trauma.

How Should I Structure My System Design Answer?

Structure your response in five phases, each with a specific deliverable that signals pharmaceutical fluency. Phase one: requirement clarification with explicit regulatory classification. State within your first 90 seconds whether this system is GxP-affected (GMP, GCP, GLP) or non-GxP, because this determines your entire validation approach. Phase two: data flow with ALCOA+ annotation. Every arrow on your diagram needs a corresponding metadata field: who recorded this, when, from what system, with what electronic signature. Phase three: risk-based validation strategy. Reference ICH Q9 quality risk management; identify which components require IQ/OQ/PQ (Installation, Operational, Performance Qualification) and which can use lighter validation. Phase four: business continuity with inspection readiness. How does the system operate during an regulatory inspection? How do you demonstrate data integrity without system downtime? Phase five: post-market surveillance integration. How does this system feed pharmacovigilance if it touches patient data?

In a January 2025 debrief, a candidate for the Clinical Data Platforms team structured exactly this way. The hiring committee debated for 22 minutes whether to give a "strong hire" or "lean hire." The deciding factor was not technical depth but regulatory fluency: the candidate had spontaneously referenced 21 CFR Part 11.10(a) (validation of systems to ensure accuracy, reliability, and consistent performance) when discussing electronic signatures. This was not rehearsed jargon; the candidate had previously worked at Medidata and described how they had handled FDA Form 483 observations. That specificity closed the loop.

The script you can use verbatim: "Before I design, I need to classify this system against GxP boundaries, because that determines whether we need full CSV with documented evidence, or whether we can operate under a lighter risk-based approach. My default assumption for anything touching clinical or manufacturing data is GxP-affected." This single opening has separated candidates in three separate debriefs I have reviewed.

What System Design Topics Actually Come Up at Eli Lilly?

Based on interview reports from yimu sanfendi and direct debrief knowledge, four domains dominate. Domain one: clinical trial data management platforms. Design a system for capturing, cleaning, and locking eCRF (electronic Case Report Form) data with appropriate edit checks, audit trails, and database lock procedures. The trap: candidates optimize for query performance when the actual constraint is the database lock—once locked for regulatory submission, data must be immutable with cryptographic integrity verification.

Domain two: supply chain serialization and track-and-trace. Design a system meeting DSCSA (Drug Supply Chain Security Act) requirements for pharmaceutical distribution. The specific challenge: interoperable exchange of transaction information, transaction history, and transaction statement across trading partners, with verification at the package level. Candidates from Amazon supply chain roles often over-optimize for velocity; DSCSA compliance requires deliberate friction at each transfer point.

Domain three: patient support program platforms with adverse event capture. Design a digital therapeutic or patient app that must detect and escalate potential adverse events to pharmacovigilance. The regulatory trap: any patient-reported outcome that suggests a safety issue triggers the 15-day expedited reporting to FDA, which means your system needs real-time triage, not batch processing.

Domain four: manufacturing execution systems (MES) with batch records. Design electronic batch record systems that replace paper-based manufacturing records. The depth here is extraordinary: candidates must understand electronic signatures for batch release, material genealogy tracking, and deviation management with CAPA (Corrective and Preventive Action) integration.

In a 2024 hiring committee for the Manufacturing Digital team, a candidate with a pure tech background proposed a "serverless microservices architecture" for electronic batch records. The hiring manager's written feedback: "Does not understand that MES validation requires fixed infrastructure with change control. Serverless is incompatible with CSV." The candidate was rejected despite strong product sense.

How Do I Demonstrate Product Judgment Rather Than Just Technical Knowledge?

Lilly system design interviews feature a specific trap: the regulatory constraint versus business value trade-off. A typical scenario: "We can build this with full CSV in 18 months, or use a lighter approach and ship in 9 months, but with residual regulatory risk. What do you recommend?" The wrong answer is purely technical; the right answer demonstrates risk-adjusted product judgment.

The script: "I would classify this against the GAMP 5 software category framework. If this is Category 5 software with direct patient impact, the 18-month validated path is non-negotiable, and I would build the business case around reduced inspection risk and faster regulatory approval. If this is Category 3 infrastructure with no direct GxP impact, I would propose a risk-based approach with documented rationale, but only after explicit sign-off from Quality Assurance and Regulatory Affairs." This answer demonstrates that you understand the decision authority does not rest with Product alone.

In a debrief from late 2024, a candidate for Digital Therapeutics used this exact framing for a patient-facing app. The hiring manager reported: "First candidate who did not try to own the compliance decision. Understood this is a cross-functional governance question." The candidate received an offer at $198,000 base with $35,000 sign-on.

The deeper insight: at Eli Lilly, product judgment is defined as the ability to operate within a matrix where Quality, Regulatory, Medical, and Legal have veto power. Your system design must explicitly name who approves each decision, not imply that Product drives unilaterally.

The Preparation Playbook

• Map every system design practice question to its regulatory analogue: if practicing "design Twitter," reframe as "design a patient community with adverse event detection"
• Internalize ALCOA+ and be able to annotate any data flow diagram with its six principles: Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available
• Work through a structured preparation system (the PM Interview Playbook covers pharma-specific system design with real Eli Lilly debrief examples, including the 2024 Manufacturing Digital MES case and Clinical Data Platforms adverse event triage flow)
• Practice drawing system diagrams with audit trail as the first component, not an afterthought
• Memorize three specific FDA guidance documents: Data Integrity and Compliance With CGMP (2018), Computer Software Assurance for Production and Quality System Software (2022), and the relevant ICH guidelines for your target domain
• Prepare one detailed scenario from your own experience where you navigated a regulatory constraint; be ready to deploy it when the interviewer asks for a time you "dealt with ambiguity"
• Time yourself: your opening regulatory classification should take 60-90 seconds, your full structured response 15-18 minutes, leaving 5-7 minutes for deep-dive questions

Blind Spots That Sink Candidacies

GOOD: "I would evaluate whether a microservices architecture meets our validation requirements; each independently deployable service requires separate IQ/OQ/PQ documentation, which may multiply validation burden beyond proportional value. For GxP systems, I default to validated monoliths with rigorous change control unless there is explicit regulatory and quality sign-off for service decomposition."

BAD: "We can iterate quickly and roll back if there's an issue."

GOOD: "In a validated environment, 'roll back' requires documented change control with impact assessment, re-qualification of affected functions, and potentially regulatory notification. I would design for forward-fix with validated patches, not rollback, and maintain parallel environments for pre-deployment verification."

BAD: "The user experience should be seamless and frictionless."

GOOD: "For prescriber-facing systems, I would design intentional friction at critical safety checkpoints—requiring explicit confirmation of contraindication review, for example—because in pharma, some friction is regulatory requirement, not UX failure. The patient safety outcome outweighs engagement metrics."

FAQ

Your judgment signal must shift from domain expertise to structured learning velocity. In a 2024 debrief, a candidate from Stripe with no pharma experience advanced by explicitly framing their first six questions around regulatory classification, then stating: "I am operating from first principles here, so I want to validate my GxP boundary assumptions." The hiring manager rated them "exceptional judgment" for knowing what they did not know. The risk: faking fluency. One candidate referenced "GxP" repeatedly but could not define it when pressed; the debrief ended in 12 minutes.

How many system design rounds should I expect, and how do they differ?

Most candidates experience one dedicated system design round of 45-60 minutes, plus system design elements embedded in two other interviews (typically with Engineering and Quality partners). The dedicated round tests full architectural thinking; the embedded rounds test your ability to collaborate with technical and quality stakeholders under time pressure. Total interview loop: 5-6 rounds across two days. Timeline from recruiter screen to offer: typically 4-6 weeks, with one candidate in 2025 reporting 9 weeks due to hiring committee scheduling around quarterly planning.

What compensation should I negotiate for, and what is actually negotiable?

For PM roles in 2026, expect $165,000-$210,000 base depending on level (PM vs. Senior PM), 15-25% target bonus, and equity equivalent through Lilly's long-term incentive plan (typically stock options or performance shares vesting over 3-4 years). Sign-on bonuses range from $15,000-$40,000 for competitive candidates. The negotiable element is often sign-on and relocation, not base; Lilly's compensation structure is relatively rigid within bands. One candidate in late 2024 successfully negotiated a $30,000 sign-on by demonstrating a competing offer from Roche with precise documentation. The script: "I am strongly motivated by Lilly's portfolio in metabolic disease, and I want to align on total compensation that reflects my market position."

---

Ready to build a real interview prep system?

Get the full PM Interview Prep System →

The book is also available on Amazon Kindle.